OncoPep licensed an autologous multi-tumor antigen adoptive T cell (MTAA) approach from MANA Therapeutics in 2020. MTAA leverages the patient’s immune system pathways to stimulate their T cells in order to target multiple antigens expressed by their tumors, without the need for genetic engineering. Targeting multiple tumor antigens at once may limit the opportunity for the tumor to “escape”, which can happen with many single-target therapies. The MTAA approach is designed to enable a broad, robust, and durable attack on the tumor, while limiting the toxicities associated with other cell, chemo, and radiation therapies that often result in severe and debilitating side effects for patients.
OncoPep is developing MTAA-420, a promising ex vivo therapy, as an immunotherapeutic for the treatment of multiple myeloma (MM).
• • •